Market open
BioAtla/$BCAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioAtla
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Ticker
$BCAB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
61
ISIN
US09077B1044
Website
BioAtla Metrics
BasicAdvanced
$28M
-
-$1.21
-
-
Price and volume
Market cap
$28M
52-week high
$3.32
52-week low
$0.24
Average daily volume
608K
Financial strength
Current ratio
2.345
Quick ratio
2.022
Total debt to equity
101.28
Management effectiveness
Return on assets (TTM)
-65.79%
Return on equity (TTM)
-246.21%
Valuation
Price to revenue (TTM)
2.198
Price to book
50.5
Price to tangible book (TTM)
50.5
Price to free cash flow (TTM)
-0.421
Growth
Earnings per share change (TTM)
-51.36%
3-year revenue growth (CAGR)
253.03%
3-year earnings per share growth (CAGR)
-24.79%
What the Analysts think about BioAtla
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for BioAtla stock.
BioAtla Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BioAtla Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BioAtla News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for BioAtla stock?
BioAtla (BCAB) has a market cap of $28M as of May 09, 2025.
What is the P/E ratio for BioAtla stock?
The price to earnings (P/E) ratio for BioAtla (BCAB) stock is 0 as of May 09, 2025.
Does BioAtla stock pay dividends?
No, BioAtla (BCAB) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next BioAtla dividend payment date?
BioAtla (BCAB) stock does not pay dividends to its shareholders.
What is the beta indicator for BioAtla?
BioAtla (BCAB) does not currently have a Beta indicator.